Audit: QRS - Bumetanide for Health & Longevity

Audit conducted on 11/10/2026 03:25 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All At-a-Glance, Protocol, Time-to-effect, tier, gate, monitoring and qualitative entries trace to ER text (e.g., Therapeutic Protocol lines 355-365, Practical Considerations line 388, Monitoring table lines 410-419).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“(theoretical)” qualifiers carried over (Key Interactions); “Unknown” cognitive time-to-effect mirrors ER line 388; “unproven” mirrors Conclusion.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication and interaction verbs (avoid/monitor/caution) match ER; no claim strengthened or softened.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Each fact stays in its ER category (contraindications from “Populations who should avoid”, interactions from the interaction lists, tiers from Benefits/Risks).
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names, NCT IDs or brand names appear.
1.6	The QRS does not introduce new attributions.	🟢	No attributions introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Cautious, evidence-weighted tone of ER Conclusion preserved.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Gate verbs are the ER’s own interaction labels.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No direct address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms glossed (anuria, hepatic coma, BUN, oliguria, QT-prolonging, SGLT2 inhibitors, eGFR, audiogram, diuresis).
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-Glance frames downsides for “health-focused adults without fluid buildup”, matching ER Conclusion.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” wording.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“prescription medication”, “orally” used; no consumer-grade route phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, visible tier labels and column headers unchanged.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present (page_title, header_, at_a_glance, action_1-3_, time_1-3*, benefits, stop_items, caution_items, risks_, marker_#*, monitoring_cadence, qualitative_item#).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	CSS, website=”evidence_review”/”audit”/”full_review” spans and footer unchanged (diff vs template).

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	No empty ER section requiring empty-state phrasing; empty Medium benefit tier handled per 12.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “No established longevity protocol”, “Approved edema regimen”, “Time of day” and interaction labels follow ER bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Sections condensed (interactions grouped by action verb, example lists trimmed); no second-page extension designed.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration is quoted (“00:00”), which contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.8 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1011-0300
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Bumetanide for Health & Longevity - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	10/11/2026 from 2026-1011-0300.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Bumetanide, a strong prescription medication that makes the kidneys flush out salt and water”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER Conclusion lines 443-447.
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words (script count).
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or specialist classifications.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 8 ER “Populations who should avoid Bumetanide” bullets (lines 327-334) present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(until corrected)”, “(only if benefit justifies fetal risk)”, “during treatment”, “(prohibited at all times)” preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in the ER contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated; ER identifies populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Lithium (a contraindication) excluded; warfarin omitted as ER states “No interaction”.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists and “(theoretical)” qualifiers preserved in condensed form.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in the ER interactions.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Derived from ER Therapeutic Protocol (lines 355-365).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Longevity status, approved regimen (with older-adult low-end start), and time of day.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides more than three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Diuresis 30-60 min, blood pressure 6 weeks, cognitive effect unknown (ER line 388).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High (fluid overload) then Low-tier benefits (blood pressure, Alzheimer’s risk) in ER tier order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects present in the ER.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Empty Medium tier span set to display: none.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers have items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 10 ER table biomarkers listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Cadence mirrors ER line 406.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 6 ER qualitative markers listed.

Issues 11/10/2026 03:25

Pass rate 100.00%. No issues found.

Issues 11/10/2026 03:22

1. 2.7 — Unexplained jargon in interactions: The Key Interactions gate (lines 556–559) uses “Nephrotoxic drugs”, “QT-prolonging drugs”, and “SGLT2 inhibitors” without plain-language explanations, though the ER provides them (“drugs that delay heart electrical recovery”, “drugs that make the kidney excrete glucose”, “direct kidney toxicity”).

Fixes 11/10/2026 03:22

1. 2.7 — Plain-language interaction explanations: In the Key Interactions gate, added the ER-supported explanations “kidney-toxic” to Nephrotoxic drugs, “drugs that make the kidney excrete glucose” to SGLT2 inhibitors, and “drugs that delay heart electrical recovery” to QT-prolonging drugs.

Issues 11/10/2026 03:18

1. 2.4 / 2.5 — Imperative dosing advice in protocol: action_2_sub (line 461) ends with “start at low end of range in older adults”, a bare instruction; the ER presents this as “The label advises starting at the low end of the range in older adults”.
2. 2.8 — Duplicated diuresis duration text: action_3_sub (line 472) repeats “largely complete within 4 hours at 1–2 mg”, which already appears as time_1_sub (line 489).

Fixes 11/10/2026 03:18

1. 2.4 / 2.5 — Imperative dosing advice removed: Changed action_2_sub ending from “start at low end of range in older adults” to “label advises low-end start in older adults”, presenting the label’s guidance as in the ER.
2. 2.8 — Duplicated diuresis text removed: Shortened action_3_sub to “Avoids nighttime urination”; the 4-hour duration remains in time_1_sub only.

Issues 11/10/2026 03:17

1. 1.1 — Older-adult dosing qualifier altered: Protocol cell action_2_sub (line 461) reads “low end of range in older adults”, whereas the ER Age bullet (line 365) says the label advises starting at the low end of the range in older adults.

Fixes 11/10/2026 03:17

1. 1.1 — Older-adult dosing qualifier: Changed action_2_sub from “low end of range in older adults” to “start at low end of range in older adults” to match the ER Age bullet.

Issues 11/10/2026 03:12

1. 4.5 — Interaction gate exceeds page budget: The Key Interactions gate (lines 554-573) lists all 18 ER interactions as separate items, several sharing the same action (five separate “monitor (theoretical)” items), so the sheet runs well beyond one A4 page instead of being condensed.
2. 12.4 — Parenthetical kept in benefit: [benefits_high] (line 522) reads “Reduction of fluid overload (edema)”, preserving the ER heading’s parenthetical instead of stripping it.

Fixes 11/10/2026 03:12

1. 4.5 — Condensed interaction gate: Merged the 18 Key Interactions items into 7 by grouping items that share the same action (avoid, monitor, caution, caution (theoretical), monitor (theoretical)), keeping every ER label and example list verbatim.
2. 12.4 — Stripped benefit parenthetical: Changed [benefits_high] from “Reduction of fluid overload (edema)” to “Reduction of fluid overload”.

Issues 11/10/2026 03:10

1. 2.7 — Unexplained jargon in sheet: “diuresis” in [action_3_sub] (line 472) appears before any plain-language gloss, and “sulfonamide allergy” in [stop_items] (line 543) is not explained, although the ER glosses it as sulfa allergy.

Fixes 11/10/2026 03:10

1. 2.7 — Unexplained jargon replaced: Changed “diuresis largely complete” in [action_3_sub] to “increased urine flow largely complete” and “caution with sulfonamide allergy” in [stop_items] to “caution with sulfonamide, or sulfa, allergy”.

Issues 11/10/2026 03:07

1. 1.2 — Creatinine target qualifier dropped: marker_4_target (QRS line 628) omits “(standard reference range)” after the creatinine range, which the ER Monitoring table carries (ER line 413) and which every other numeric target in the QRS retains.

Fixes 11/10/2026 03:07

1. 1.2 — Creatinine target qualifier restored: Added “(standard reference range)” after the creatinine ranges in marker_4_target, matching the ER Monitoring table wording.

Issues 11/10/2026 03:03

1. 1.3 — Beneficial verdict dropped: The potassium and magnesium supplements item (line 570) shows only “caution if also taking potassium-sparing drugs (spironolactone)”, omitting the ER verdict “Beneficial” and presenting it as a pure caution.
2. 2.7 — Unexplained specialist abbreviations: “BUN” (line 544), “eGFR” (line 627), “APOE4” (line 594), and “Audiogram” (line 657) appear without the plain-language explanations the ER provides.
3. 2.13 / 7.2 — Audience verdict missing: At a Glance (line 433) omits the Conclusion’s verdict that for health-focused adults without fluid retention the downsides are frequent and predictable while the brain benefit is unproven.
4. 4.5 — Exceeds one A4 page: Key Interactions (lines 555-572) keep full example lists and the monitoring cadence (line 665) is long, so the sheet is not condensed toward the one-page budget.

Fixes 11/10/2026 03:03

1. 1.3 — Beneficial verdict restored: Changed the potassium and magnesium supplements item from “caution if also taking potassium-sparing drugs” to “beneficial; caution if also taking potassium-sparing drugs”, matching the ER.
2. 2.7 — Abbreviations explained: Added “(blood urea nitrogen)” after BUN, “(estimated kidney filtration rate)” after eGFR, “(hearing test)” after Audiogram, and changed “without APOE4” to “without the APOE4 gene variant”.
3. 2.13 / 7.2 — Audience verdict added: Reworded At a Glance (69 words) to say that for health-focused adults without fluid buildup, low potassium, dehydration, and dizziness on standing are frequent, predictable downsides.
4. 4.5 — Condensed toward one page: Trimmed example lists in four Key Interactions items (blood-pressure drugs, thiazide diuretics, diuretic herbs, blood-pressure-lowering supplements) and shortened the monitoring cadence sentence.